The aftermath of the Merck's HIV vaccine trial
<p>Abstract</p> <p>The recently released results of the Merck's Phase IIb "test-of concept" vaccine trials have shown no protection from HIV-1 infection in the vaccinated group compared with a control group vaccinated with placebo. The study was designed to test the...
Main Authors: | Quinto Ileana, Fiume Giuseppe, Schiavone Marco, Iaccino Enrico, Scala Giuseppe |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2008-07-01
|
Series: | Retrovirology |
Online Access: | http://www.retrovirology.com/content/5/1/56 |
Similar Items
-
Merck Manuals
by: Krystal Bullers
Published: (2017-01-01) -
Merck Serono Geneva /
by: Jahn, Helmut, et al.
Published: (2008) -
Role of Chronic Lymphocytic Leukemia (CLL)-Derived Exosomes in Tumor Progression and Survival
by: Nancy Nisticò, et al.
Published: (2020-09-01) -
Phage-Displayed Peptides for Targeting Tyrosine Kinase Membrane Receptors in Cancer Therapy
by: Annamaria Aloisio, et al.
Published: (2021-04-01) -
Merck's actions surrounding Vioxx.
by: Michael Heinley
Published: (2006-06-01)